Public filings / SYRE on Yahoo Finance (opens in a new tab)
SYRE: insider buying, 13F holders, analyst moves
Spyre Therapeutics Inc - US
A summary of public filings about Spyre Therapeutics Inc - US. For the latest insider history, price chart, analyst changes and activist filings, open the live lookup.
SEC Form 13F · Q2 2026
4 of our 100 managers hold SYRE
Combined reported value $796.7M; 2 sold out since Q1 2026.
Holders among our 100 managers: 2 in Q3 2023, 4 in Q2 2026.
| Manager | Value | % of portfolio | Change vs Q1 2026 |
|---|---|---|---|
| Perceptive Advisors | $383.5M | 5.95% | Added |
| RTW Investments | $377.5M | 3.22% | Added |
| Samlyn Capital | $35.5M | 0.59% | Added |
| Tudor Investment | $235K | 0.00% | Trimmed |
Important information
Facts from public SEC filings, shown for information only. Not a recommendation. Not individualized investment advice. Gulfstream Capital and its clients may hold positions in securities shown.